Prof. Giampaolo Bianchini is a specialist in medical oncology, with a particular focus on breast cancer.
He is the Head of Breast Oncology in the Department of Medical Oncology at IRCCS Ospedale San Raffaele, Italy.
He is also an Associate Professor at Vita-Salute San Raffaele University.
He has nearly 25 years of clinical experience managing patients with early-stage and metastatic breast cancer, according to the supplied biography.
His clinical expertise includes the assessment and treatment of breast cancer at different stages of the disease.
He has a strong research interest in developing new cancer therapies, including immunotherapy approaches for breast cancer.
He is responsible for the translational clinical research and immunotherapy group within the Department of Medical Oncology.
His research focuses on understanding how breast cancers respond or become resistant to treatment, identifying new therapeutic strategies, and investigating biomarkers that may help personalize treatment.
He has undertaken research training at leading American institutions, including the National Cancer Institute in Bethesda, MD Anderson Cancer Center in Houston, and Yale Cancer Center in New Haven.
He has authored numerous scientific publications in international journals, including Nature, The Lancet, Annals of Oncology, The Lancet Oncology, Journal of Clinical Oncology, and Nature Medicine.
Degree in Medicine and Surgery - University of Milano-Bicocca, Italy, 2000
Specialization in Medical Oncology - University of Milan, Italy, 2004
Prof. Andrea Necchi is a medical oncologist specialising in genitourinary cancers, including bladder, kidney, prostate, testicular, and penile cancers.
He works in the Medical Oncology Unit at IRCCS Ospedale San Raffaele in Milan, Italy, where he directs the Strategic Research Programme in Genitourinary Tumours.
He is an Associate Professor of Medical Oncology at Vita-Salute San Raffaele University in Milan.
He has extensive clinical and research experience in the multidisciplinary treatment of urological malignancies.
He has been a leading investigator in the development of neoadjuvant immunotherapy strategies for muscle-invasive bladder cancer, including research through the PURE-01 clinical trial.
His research interests include immunotherapy, targeted therapies, precision oncology, and the development of new treatments for advanced and rare genitourinary cancers.
He has experience in clinical trials involving bladder cancer, testicular cancer, penile cancer, kidney cancer, and prostate cancer.
His research group conducts clinical and translational studies, including early-phase clinical trials for selected patients with genitourinary malignancies.
He is involved in international oncology research and serves on scientific committees for organisations such as the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the European Association of Urology (EAU).
He is a co-founder and vice-president of the Global Society of Rare Genitourinary Tumours and has contributed to patient-support initiatives for people affected by bladder and kidney cancers.
According to the supplied biography, he has authored or co-authored approximately 570 scientific publications and book chapters.
Degree in Medicine and Surgery - University of Milan, Italy, 2004, with honors
Specialisation in Medical Oncology - University of Milan, Italy, 2008, with honors
Fellow of the American Society of Clinical Oncology (FASCO) - Designated in July 2026, according to the supplied biography.
Genitourinary medical oncology
Bladder cancer treatment
Neoadjuvant immunotherapy for muscle-invasive bladder cancer
